Barclays’s Relmada Therapeutics RLMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
– Sell
-2,100
Closed -$7.33K – 5304
2022
Q4
$7.33K Buy
+2,100
New +$18.4K ﹤0.01% 4960

Other funds holding RLMD

Barclays's RLMD Position: Q3 2026 in Review

Barclays reduced its Relmada Therapeutics (RLMD) stake by 22% in Q3 2026, selling an estimated $56.1K and leaving 39,798 shares worth $150K. The position accounts for ﹤0.01% of the portfolio, ranked #4129.

Barclays first reported a position in RLMD in Q1 2022 and has held it in 18 quarters since. The position peaked at $679K in Q1 2024. 133 funds tracked by Wall St. Rank hold RLMD as of Q3 2026.

  • Barclays held 39,798 shares of Relmada Therapeutics worth $150K as of Q3 2026.
  • Barclays sold 11,436 Relmada Therapeutics shares in Q3 2026, an estimated $56.1K.
  • Relmada Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4129 holding.
  • Barclays first reported a position in Relmada Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Relmada Therapeutics position peaked at $679K in Q1 2024.
  • 133 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.